CAB-B7-H3

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameCAB-B7-H3
Drug Alias NameCAB-B7-H3CAB B7-H3CABB7-H3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CD3Anti-CD276
TargetsT cell surface glycoprotein CD3CD276 antigen
Therapy Area/IndicationsProstatic NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHimalaya Therapeutics HK Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHimalaya Therapeutics HK Ltd
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A